ALK and non-small cell lung carcinoma: Different molecular oncogene addiction drivers have been identified in NSCLC, particularly in adenocarcinomas, including EGFR mutations, ALK and ROS1 rearrangements, MET mutations and amplifications, BRAF and KRAS mutations, RET fusions, NTRK fusions, and HER2 mutations, among others [1,2].